Factor | Mean rating | Min-max | SD |
---|---|---|---|
Proven effect and patient benefit of the drug | 2.96 | 2-3 | 0.19 |
Strength and quality of the scientific evidence | 2.85 | 2-3 | 0.36 |
Prescriber's knowledge and experience | 2.52 | 1-3 | 0.58 |
Patient's level of disease activity | 2.40 | 0-3 | 1.01 |
National and professional guidelines | 2.39 | 1-3 | 0.63 |
Colleagues | 2.11 | 1-3 | 0.58 |
Local guidelines | 2.08 | 0-3 | 0.92 |
Prescriber's attitude to biologics | 1.96 | 0-3 | 0.98 |
Cost-effectiveness of biologics | 1.93 | 0-3 | 0.78 |
Formal leaders at the department | 1.85 | 1-3 | 0.66 |
Economic resources and pharmaceutical budget | 1.78 | 0-3 | 0.75 |
Cost of the drug | 1.70 | 0-3 | 0.87 |
Economic consequences for the department | 1.70 | 0-3 | 0.87 |
Study participation by the prescriber | 1.44 | 0-3 | 0.88 |
Informal leaders at the department | 1.41 | 0-3 | 0.84 |
Feedback (from colleagues, leaders, statistics) | 1.31 | 0-3 | 0.61 |
Mode of prescription (if taking it is complicated) | 1.29 | 0-3 | 0.70 |
Patient's expressed requests and wishes | 1.04 | 0-2 | 0.50 |
Non-disease-related attributes of the patient | 0.93 | 0-3 | 0.62 |
Information/marketing from the pharmaceutical company | 0.81 | 0-2 | 0.48 |
Media attention in newspapers, TV | 0.43 | 0-1 | 0.49 |